• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Protagonist Therapeutics Inc (NQ: PTGX )

    40.70 -0.34 (-0.84%)
    Streaming Delayed Price Updated: 1:20 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Protagonist Therapeutics Inc

    < Previous 1 2 3 4 5 6 Next >
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
    Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
    Via Benzinga
    PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024
    PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
    Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
    Via Benzinga
    The Latest Analyst Ratings for Protagonist Therapeutics
    Via Benzinga
    What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
    Via Benzinga
    Expert Ratings for Protagonist Therapeutics
    Via Benzinga
    Where Protagonist Therapeutics Stands With Analysts
    Via Benzinga
    AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    3 Growth Stocks No One Is Watching (But They Should Be)
    While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential. 
    Via InvestorPlace
    Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
    Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    The 3 Best Biotech Stocks to Buy in June 2024
    Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
    Via InvestorPlace
    PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
    PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Chart Of The Day: Protagonist Therapeutics - Wide Opinions
    Via Talk Markets
    Protagonist Therapeutics: Q1 Earnings Insights
    Via Benzinga
    Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
    Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
    Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. 
    Via The Motley Fool
    Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning. 
    Via InvestorPlace
    Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
    JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,  
    Via Benzinga
    Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
    Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at... 
    Via Benzinga
    Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
    Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. 
    Via Benzinga
    AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
    U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
    Via Benzinga
    US Stocks Mixed; Dow Falls Over 50 Points
    U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%... 
    Via Benzinga
    Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
    Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of  
    Via Benzinga
    Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
    The company is targeting psoriasis with a first-ever mechanism that could rival leaders. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.